A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics.

Adolescent Adult Animals Antigens, Helminth / blood Antiparasitic Agents / pharmacology Cytokines / blood Female Humans Immunity, Humoral / drug effects Immunoglobulin M / blood Male Middle Aged Models, Biological Praziquantel / pharmacology Schistosoma mansoni / drug effects Schistosomiasis mansoni / blood Vaccines / immunology Young Adult

Journal

Nature medicine

ISSN: 1546-170X

Titre abrégé: Nat Med

Pays: United States

ID NLM: 9502015

Informations de publication

Date de publication:
03 2020

Historique:

received: 06 06 2019

accepted: 09 01 2020

pubmed: 19 2 2020

medline: 9 4 2020

entrez: 19 2 2020

Statut: ppublish

Résumé

Schistosomiasis treatment relies on the use of a single drug, praziquantel, which is insufficient to control transmission in highly endemic areas

Identifiants

DOI: 10.1038/s41591-020-0759-x PMID: 32066978

pubmed: 32066978

doi: 10.1038/s41591-020-0759-x

pii: 10.1038/s41591-020-0759-x

doi:

Substances chimiques

Antigens, Helminth 0

Antiparasitic Agents 0

Cytokines 0

Immunoglobulin M 0

Vaccines 0

Praziquantel 6490C9U457

Banques de données

ClinicalTrials.gov

['NCT02755324']

Types de publication

Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

326-332

Références

King, C. H. et al. Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. PLoS Negl. Trop. Dis. 5, e1321 (2011).

doi: 10.1371/journal.pntd.0001321 pubmed: 21949893 pmcid: 21949893

Tukahebwa, E. M., Vennervald, B. J., Nuwaha, F., Kabatereine, N. B. & Magnussen, P. Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda. Trans. R. Soc. Trop. Med. Hyg. 107, 397–404 (2013).

doi: 10.1093/trstmh/trt024 pubmed: 23596262 pmcid: 23596262

Bergquist, R., Utzinger, J. & Keiser, J. Controlling schistosomiasis with praziquantel: how much longer without a viable alternative? Infect. Dis. Poverty 6, 74 (2017).

doi: 10.1186/s40249-017-0286-2 pubmed: 28351414 pmcid: 28351414

Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386, 743–800 (2015).

doi: 10.1016/S0140-6736(15)60692-4

Colley, D. G., Bustinduy, A. L., Secor, W. E. & King, C. H. Human schistosomiasis. Lancet 383, 2253–2264 (2014).

doi: 10.1016/S0140-6736(13)61949-2 pubmed: 24698483 pmcid: 24698483

Merrifield, M. et al. Advancing a vaccine to prevent human schistosomiasis. Vaccine 34, 2988–2991 (2016).

doi: 10.1016/j.vaccine.2016.03.079 pubmed: 27036511 pmcid: 27036511

Santini-Oliveira, M. et al. Schistosomiasis vaccine candidate Sm14/GLA-SE: phase 1 safety and immunogenicity clinical trial in healthy male adults. Vaccine 34, 586–594 (2016).

doi: 10.1016/j.vaccine.2015.10.027 pubmed: 26571311 pmcid: 26571311

Zhang, W. et al. Sm-p80-based schistosomiasis vaccine: double-blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite transmission-blocking efficacy. Ann. NY Acad. Sci. 1425, 38–51 (2018).

doi: 10.1111/nyas.13942 pubmed: 30133707 pmcid: 30133707

Status of Vaccine Research and Development of Vaccines for Schistosomiasis (World Health Organization, 2014); http://who.int/immunization/research/meetings_workshops/Schistosomiasis_VaccineRD_Sept2014.pdf

Mo, A. X. & Colley, D. G. Workshop report: schistosomiasis vaccine clinical development and product characteristics. Vaccine 34, 995–1001 (2016).

doi: 10.1016/j.vaccine.2015.12.032 pubmed: 26721329 pmcid: 26721329

Siddiqui, A. J. et al. Sm-p80-based vaccine trial in baboons: efficacy when mimicking natural conditions of chronic disease, praziquantel therapy, immunization, and Schistosoma mansoni re-encounter. Ann. NY Acad. Sci. 1425, 19–37 (2018).

doi: 10.1111/nyas.13866 pubmed: 29888790 pmcid: 29888790

Roestenberg, M., Hoogerwerf, M. A., Ferreira, D. M., Mordmuller, B. & Yazdanbakhsh, M. Experimental infection of human volunteers. Lancet Infect. Dis. 18, e312–e322 (2018).

doi: 10.1016/S1473-3099(18)30177-4 pubmed: 29891332 pmcid: 29891332

Langenberg, M. C. C. et al. Katayama syndrome without Schistosoma mansoni eggs. Ann. Intern. Med. 170, 732–733 (2019).

doi: 10.7326/L18-0438 pubmed: 30615787 pmcid: 30615787

Balasingam, S. & Wilder-Smith, A. Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies. Int. J. Infect. Dis. 49, 18–29 (2016).

doi: 10.1016/j.ijid.2016.05.013 pubmed: 27208631 pmcid: 27208631

Walk, J. et al. Diagnosis and treatment based on quantitative PCR after controlled human malaria infection. Malar. J. 15, 398 (2016).

doi: 10.1186/s12936-016-1434-z pubmed: 27495296 pmcid: 27495296

Jin, C. et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella typhi: a randomised controlled, phase 2b trial. Lancet 390, 2472–2480 (2017).

doi: 10.1016/S0140-6736(17)32149-9 pubmed: 28965718 pmcid: 28965718

Chen, W. H. et al. Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor. Clin. Infect. Dis. 62, 1329–1335 (2016).

doi: 10.1093/cid/ciw145 pubmed: 27001804 pmcid: 27001804

Rocha, M. O. et al. Pathogenetic factors of acute Schistosomia mansoni: correlation of worm burden, IgE, blood eosinophilia and intensity of clinical manifestations. Trop. Med. Int. Health 1, 213–220 (1996).

doi: 10.1111/j.1365-3156.1996.tb00029.x pubmed: 8665387 pmcid: 8665387

van Grootveld, R. et al. Improved diagnosis of active Schistosoma infection in travellers and migrants using the ultra-sensitive in-house lateral flow test for detection of circulating anodic antigen (CAA) in serum. Eur. J. Clin. Microbiol. Infect. Dis. 37, 1709–1716 (2018).

doi: 10.1007/s10096-018-3303-x pubmed: 29974279 pmcid: 29974279

Meltzer, E. & Schwartz, E. Schistosomiasis: current epidemiology and management in travelers. Curr. Infect. Dis. Rep. 15, 211–215 (2013).

doi: 10.1007/s11908-013-0329-1

Visser, L. G., Polderman, A. M. & Stuiver, P. C. Outbreak of schistosomiasis among travelers returning from Mali, West Africa. Clin. Infect. Dis. 20, 280–285 (1995).

doi: 10.1093/clinids/20.2.280

Sousa, M. S. et al. Performance of an ultra-sensitive assay targeting the circulating anodic antigen (CAA) for detection of Schistosoma mansoni infection in a low endemic area in Brazil. Front. Immunol. 10, 682 (2019).

doi: 10.3389/fimmu.2019.00682 pubmed: 6458306 pmcid: 6458306

Kariuki, T. M. et al. Parameters of the attenuated schistosome vaccine evaluated in the olive baboon. Infect. Immun. 72, 5526–5529 (2004).

doi: 10.1128/IAI.72.9.5526-5529.2004 pubmed: 517471 pmcid: 517471

Corstjens, P. L. et al. Tools for diagnosis, monitoring and screening of Schistosoma infections utilizing lateral-flow based assays and upconverting phosphor labels. Parasitology 141, 1841–1855 (2014).

doi: 10.1017/S0031182014000626 pubmed: 4265670 pmcid: 4265670

Colley, D. G. et al. A five-country evaluation of a point-of-care circulating cathodic antigen urine assay for the prevalence of Schistosoma mansoni. Am. J. Trop. Med. Hyg. 88, 426–432 (2013).

doi: 10.4269/ajtmh.12-0639 pubmed: 3592520 pmcid: 3592520

Caldas, I. R. et al. Human Schistosoma mansoni: immune responses during acute and chronic phases of the infection. Acta Trop. 108, 109–117 (2008).

doi: 10.1016/j.actatropica.2008.05.027

Thompson, L. J. et al. Conditioning of naive CD4(

doi: 10.1038/ni.3329 pubmed: 4757503 pmcid: 4757503

Kariuki, T. M. & Farah, I. O. Resistance to re-infection after exposure to normal and attenuated schistosome parasites in the baboon model. Parasite Immunol. 27, 281–288 (2005).

doi: 10.1111/j.1365-3024.2005.00783.x

Soonawala, D., Geerts, J. W., de Mos, M., Yazdanbakhsh, M. & Visser, L. G. The immune response to schistosome antigens in formerly infected travelers. Am. J. Trop. Med. Hyg. 84, 43–47 (2011).

doi: 10.4269/ajtmh.2011.10-0260 pubmed: 3005525 pmcid: 3005525

Parrino, T. A., Schreiber, D. S., Trier, J. S., Kapikian, A. Z. & Blacklow, N. R. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N. Engl. J. Med. 297, 86–89 (1977).

doi: 10.1056/NEJM197707142970204 pubmed: 405590 pmcid: 405590

Sombetzki, M. et al. Host defense versus immunosuppression: unisexual infection with male or female Schistosoma mansoni differentially impacts the immune response against invading cercariae. Front. Immunol. 9, 861 (2018).

doi: 10.3389/fimmu.2018.00861 pubmed: 29743881 pmcid: 29743881

Richter, D., Harn, D. A. & Matuschka, F. R. The irradiated cercariae vaccine model: looking on the bright side of radiation. Parasitol. Today 11, 288–293 (1995).

doi: 10.1016/0169-4758(95)80041-7 pubmed: 15275325 pmcid: 15275325

Agnew, A. et al. The relationship between worm burden and levels of a circulating antigen (CAA) of five species of Schistosoma in mice. Parasitology 111, 67–76 (1995).

doi: 10.1017/S0031182000064611 pubmed: 7609992 pmcid: 7609992

Janse, J. J. et al. Establishing the production of male Schistosoma mansoni cercariae for a controlled human infection model. J. Infect. Dis. 218, 1142–1146 (2018).

doi: 10.1093/infdis/jiy275 pubmed: 29905805 pmcid: 29905805

Winkel, B. M. F. et al. Early induction of human regulatory dermal antigen presenting cells by skin-penetrating Schistosoma mansoni cercariae. Front. Immunol. 9, 2510 (2018).

doi: 10.3389/fimmu.2018.02510 pubmed: 30429854 pmcid: 30429854

World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310, 2191–2194 (2013).

doi: 10.1001/jama.2013.281053

European Commission. Clinical Trials - Directive 2001/20/EC. Official Journal of the European Communities https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_20/dir_2001_20_en.pdf (2001).

Corstjens, P. L. et al. Improved sensitivity of the urine CAA lateral-flow assay for diagnosing active Schistosoma infections by using larger sample volumes. Parasit. Vectors 8, 241 (2015).

doi: 10.1186/s13071-015-0857-7 pubmed: 25896512 pmcid: 25896512

Obeng, B. B. et al. Application of a circulating-cathodic-antigen (CCA) strip test and real-time PCR, in comparison with microscopy, for the detection of Schistosoma haematobium in urine samples from Ghana. Ann. Trop. Med. Parasitol. 102, 625–633 (2008).

doi: 10.1179/136485908X337490 pubmed: 18817603 pmcid: 18817603

Deelder, A. M. et al. Applicability of different antigen preparations in the enzyme-linked immunosorbent assay for Schistosomiasis mansoni. Am. J. Trop. Med. Hyg. 29, 401–410 (1980).

doi: 10.4269/ajtmh.1980.29.401 pubmed: 6992609 pmcid: 6992609

Nash, T. E., Ottesen, E. A. & Cheever, A. W. Antibody response to a polysaccharide antigen present in the schistosome gut. II. Modulation of antibody response. Am. J. Trop. Med. Hyg. 27, 944–950 (1978).

doi: 10.4269/ajtmh.1978.27.944 pubmed: 362958 pmcid: 362958

Deelder, A. M., van Zeyl, R. J., Fillie, Y. E., Rotmans, J. P. & Duchenne, W. Recognition of gut-associated antigens by immunoglobulin M in the indirect fluorescent antibody test for Schistosoma mansoni. Trans. R. Soc. Trop. Med. Hyg. 83, 364–367 (1989).

doi: 10.1016/0035-9203(89)90506-3 pubmed: 2515624 pmcid: 2515624

Dalton, J. P., Day, S. R., Drew, A. C. & Brindley, P. J. A method for the isolation of schistosome eggs and miracidia free of contaminating host tissues. Parasitology 115, 29–32 (1997).

doi: 10.1017/S0031182097001091 pubmed: 9226954 pmcid: 9226954

Deelder, A. M. Immunology of experimental infections with Schistosoma mansoni in the Swiss mouse and with Fasciola hepatica in the rabbit. Acta Leiden 39, 5–107 (1973).

pubmed: 4573511 pmcid: 4573511

van den Biggelaar, A. H., Borrmann, S., Kremsner, P. & Yazdanbakhsh, M. Immune responses induced by repeated treatment do not result in protective immunity to Schistosoma haematobium: interleukin (IL)-5 and IL-10 responses. J. Infect. Dis. 186, 1474–1482 (2002).

doi: 10.1086/344352 pubmed: 12404164 pmcid: 12404164

Faulkner, H. et al. Antibody responses in onchocerciasis as a function of age and infection intensity. Parasite Immunol. 23, 509–516 (2001).

doi: 10.1046/j.1365-3024.2001.00408.x pubmed: 11589780 pmcid: 11589780

Staal, S. L. et al. Prevalence of atopy following mass drug administration with albendazole: a study in school children on Flores Island, Indonesia. Int. Arch. Allergy Immunol. 177, 192–198 (2018).

doi: 10.1159/000490952 pubmed: 30130756 pmcid: 30130756

van Dam, G. J. et al. Antibody response patterns against Schistosoma mansoni in a recently exposed community in Senegal. J. Infect. Dis. 173, 1232–1241 (1996).

doi: 10.1093/infdis/173.5.1232 pubmed: 8627077 pmcid: 8627077

Bates, D., Machler, M., Bolker, B. M. & Walker, S. C. Fitting linear mixed-effects models using lme4. J. Stat. Softw. 67, 1–48 (2015).

doi: 10.18637/jss.v067.i01

Kuznetsova, A., Brockhoff, P. B. & Christensen, R. H. B. lmerTest package: tests in linear mixed effects models. J. Stat. Softw. 82, 1–26 (2017).

doi: 10.18637/jss.v082.i13

Wickham, H. ggplot2: Elegant Graphics for Data Analysis 2nd edn (Springer, 2016).

Rohart, F., Gautier, B., Singh, A. & Le Cao, K. A. mixOmics: an R package for ‘omics feature selection and multiple data integration. PLoS Comput. Biol. 13, e1005752 (2017).

doi: 10.1371/journal.pcbi.1005752 pubmed: 5687754 pmcid: 5687754

Singh, A. et al. DIABLO: an integrative approach for identifying key molecular drivers from multi-omic assays. Bioinformatics 35, 3055–3062 (2019).

doi: 10.1093/bioinformatics/bty1054